- CTI BioPharma Corp. (NASDAQ:CTIC -2.6%) Q4 results: Revenues: $17.8M (-45.9%); COGS: $0.3M (+900.0%); R&D Expense: $21.9M (+119.0%); SG&A: $13.1M (+4.8%); Operating Loss: ($39.4M) (-482.5%); Net Loss: ($44.2M) (-533.3%); Loss Per Share: ($0.27) (-437.5%).
- FY2014 results: Revenues: $60.1M (+73.2%); COGS: $0.9M (+800.0%); R&D Expense: $64.6M (+92.3%); SG&A: $56.2M (+32.9%); Operating Loss: ($86.2M) (-107.7%); Net Loss: ($96M) (-93.5%); Loss Per Share: ($0.65) (-51.2%); Quick Assets: $70.9M (+1.0%).
- 2015 Guidance: Total revenues: ~ $50M - 55M; non-GAAP operating loss: ~ $75M - 85M.